Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esmolol - NovaLead Pharma

Next Previous
Search
Drug Profile

Esmolol - NovaLead Pharma

Alternative Names: Esmolol Hydrochloride; Galnobax; VLD-02

Latest Information Update: 02 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NovaLead Pharma Pvt. Ltd
  • Class Antiarrhythmics; Antihypertensives; Ethanolamines; Foot disorder therapies; Phenols; Propionates; Skin disorder therapies; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Diabetic foot ulcer

Highest Development Phases

  • Registered Diabetic foot ulcer

Most Recent Events

  • 24 Apr 2024 Registered for Diabetic foot ulcer in India (Topical)
  • 24 Apr 2024 NovaLead Pharma plans to launch Esmolol (Galnobax®) for Diabetic foot ulcer (Topical, Gel) in India
  • 19 Sep 2022 Efficacy data from a phase III trial in Diabetic foot ulcer presented at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD-2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top